Using its proprietary technology, Socati Corp. is able to completely customize the cannabinoid profile of its hemp-derived ingredients.
Photo © Shutterstock.com/ElRoi
Socati Corp. has announced that thanks to its patented chromatographic-based technology, it can customize cannabinoid profiles for its hemp-derived ingredients. The firm has also announced ingredients based on this technology, each with a broad spectrum of cannabinoids, featuring a minimum of 80% cannabidiol (CBD) and 4% of the minor cannabinoid cannabigerol (CBG).
The first is an oil ingredient called Socati CBG NDT, and the other is a water-soluble powder formulation called Socati Soluble. With each of these products, using the chromatographic-based technology, Socati is capable of targeting and separating minor cannabinoids to create fully customizable cannabinoid profiles for consumer packaged goods (CPG) manufacturers, consistently hitting the manufacturer’s exact specifications.
“Consumers are demanding increasingly personalized products, and manufacturers are looking for ways to respond to that demand,” said Socati CEO, Josh Epstein, in a press release. “Socati’s proprietary technology creates hemp extracts that behave just like any other food ingredient, allowing CPG manufacturers address these demands.”
In the coming months, Socati has also stated that it will be offering additional products featuring customizable levels of other minor cannabinoids, including cannabinol (CBN) and cannabichromene (CBC).
“Hemp-derived cannabinoids show tremendous potential to help consumers in myriad ways,” Epstein added. “Producing ingredients that meet the standards for quality, purity, and customization that manufacturers have come to expect from all their ingredient providers will help unleash that potential.”
Socati’s Montana-based processing facility complies with Global Food Safety Initiative (GFSI)-recognized benchmarking requirements and adheres to Good Manufacturing Practice (GMP) standards for manufacturing.
Kaneka Nutrients to unveil new consumer research on menopausal women at Vitafoods Europe 2024
April 26th 2024The company will reveal the results of the research that is based on live feedback from 200 menopausal women who took 200 mg per day of Kaneka Ubiquinol over two-months, monitored the effects, and recorded their observations.
Rousselot to showcase new collagen peptide research and targeted solutions at Vitafoods Europe 2024
April 25th 2024The company will be highlighting new research that demonstrates the ability of its Peptan collagen peptide brand to support sleep quality, reduce gastrointestinal discomfort, and enhance skin health, including density, hydration, and elasticity.